AIM ImmunoTech Stock-Based Compensation

What does AIM ImmunoTech do? AIM ImmunoTech, Inc. generates revenue primarily through the sales and marketing of Alferon N Injection, an approved treatment for refractory or recurring external genital warts in patients over 18. The company also develops Ampligen, a drug in clinical development for Chronic Fatigue Syndrome, and Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon. Its primary customer segments include patients with viral and immune-based chronic disorders requiring specialized therapies. The firm's R&D segment focuses on Ampligen and other drugs under development, while its commercial segment handles Alferon product sales. Alferon N Injection is marketed for intralesional treatment of genital warts, targeting healthcare providers who prescribe it to adult patients. Ampligen is positioned for clinical trials in Chronic Fatigue Syndrome, with potential future commercialization. Alferon LDO represents a novel oral delivery method for natural interferon, targeting patients seeking non-invasive treatment options. The company's revenue streams are derived from both current product sales and future potential drug development milestones. The firm's business model centers on leveraging natural immune system enhancing technologies to address unmet medical needs in viral and immune-based disorders. Its products are developed through clinical trials and regulatory approvals, with Alferon N Injection already approved for specific indications. The company's focus on R&D and commercialization of these therapies defines its market position within the biopharmaceutical sector. AIM ImmunoTech is one of the most popular companies on Eulerpool.